U.S. company licenses rights to long-acting testosterone preparation
Indevus Pharmaceuticals, Inc., Lexington, MA has licensed exclusive U.S. rights from Schering AG, Germany to market Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism.
Indevus Pharmaceuticals, Inc., Lexington, MA has licensed exclusive U.S. rights from Schering AG, Germany to market Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism. Nebido, which was recently approved and launched in Europe, requires dosing only once every 3 months.
Under the agreement, Indevus will be responsible for the development and commercialization of the drug in the United States. Schering will be responsible for manufacturing and supplying commercial product to Indevus.
Indevus said it currently anticipates filing a new drug application with the FDA in the second half of 2006.
GU cancer diagnoses may have adverse health impacts for patients’ family members
September 12th 2024“As health care professionals, we should take a multidisciplinary approach to addressing the stress of a cancer diagnosis by helping mitigate financial toxicity, treatment burden, and emotional impact on both the patient and their family," says Mouneeb M. Choudry, MD.
